Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar 15;167(6):743-50.
doi: 10.1093/aje/kwm370. Epub 2008 Jan 17.

Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors

Affiliations

Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors

Anne M Guiltinan et al. Am J Epidemiol. .

Abstract

Hospital-based studies suggest that hepatitis C virus (HCV) infection causes frequent cirrhosis, hepatocellular carcinoma, and mortality, but epidemiologic studies have shown less morbidity and mortality. The authors performed a retrospective cohort study of 10,259 recombinant immunoblot assay-confirmed, HCV antibody-positive (HCV+), allogeneic blood donors from 1991 to 2002 and 10,259 HCV antibody-negative (HCV-) donors matched for year of donation, age, gender, and Zone Improvement Plan Code (ZIP Code). Vital status through 2003 was obtained from the US National Death Index, and hazard ratios with 95% confidence intervals were calculated by survival analysis. After a mean follow-up of 7.7 years, there were 601 (2.92%) deaths: 453 HCV+ and 148 HCV- (hazard ratio (HR) = 3.13, 95% confidence interval (CI): 2.60, 3.76). Excess mortality in the HCV+ group was greatest in liver-related (HR = 45.99, 95% CI: 11.32, 186.74), drug- or alcohol-related (HR = 10.81, 95% CI: 4.68, 24.96), and trauma/suicide (HR = 2.99, 95% CI: 2.05, 4.36) causes. There was also an unexpected increase in cardiovascular mortality among the HCV+ donors (HR = 2.21, 95% CI: 1.41, 3.46). HCV infection is associated with a significant, threefold increase in overall mortality among former blood donors, including significantly increased mortality from liver and cardiovascular causes. High rates of mortality from drug/alcohol and trauma/suicide causes are likely due to lifestyle factors and may be at least partially preventable.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Hepatitis C virus-seropositive blood donors included in the cohort, by state of residence, United States, 1991–2003. Each dot represents one donor but does not reflect his/her location within the state. Two-letter abbreviations represent US Postal Service official state abbreviations.
FIGURE 2
FIGURE 2
Age-specific survival by hepatitis C virus (HCV) status, all causes of death, United States, 1991–2003. Log-rank p < 0.0001 for lower survival in the hepatitis C virus-positive group.
FIGURE 3
FIGURE 3
Age-specific survival by hepatitis C virus (HCV) status and cause-specific mortality: liver disease (including liver cancer) (A), cardiovascular causes (B), trauma and suicide (C), and cancer (excluding liver cancer) (D), United States, 1991–2003.

References

    1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14. - PubMed
    1. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS) Hepatology. 2000;31:756–62. - PubMed
    1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899–905. - PubMed
    1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35. - PubMed
    1. Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology. 2001;34:1200–5. - PubMed

Publication types